Clinical Trial Update: Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bortezomib and docetaxel in recurrent or metastatic head and neck cancer has completed; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-04-04